Oligonucleotide compositions and methods of use thereof

Inventors

Byrne, Michael John • VATHIPADIEKAL, Vinod • Iwamoto, Naoki • Vargeese, Chandra • Guo, Lankai • Hoss, Andrew Guzior

Assignees

Wave Life Sciences Pte Ltd

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12674168-B2

Patent

Publication Date

2026-07-07

Expiration Date


Abstract

Among other things, the present disclosure provides RHO oligonucleotides, compositions, and methods. In some embodiments, provided oligonucleotides comprise nucleobase modifications, sugar modifications, internucleotidic linkage modifications and/or patterns thereof, and have improved properties, activities and/or selectivities. In some embodiments, the present disclosure provides RHO oligonucleotides, compositions and methods for preventing and/or treating RHO-related conditions, disorders or diseases, such as retinopathy (e.g, retinal degeneration, retinal degenerative disease, retinal degenerative disorder, inherited retinal degenerative disorder, retinitis pigmentosa, autosomal dominant retinitis pigmentosa, etc.).

Core Innovation

The disclosure provides chemically modified, stereodefined oligonucleotides targeting RHO featuring controlled backbone stereochemistry and modified internucleotidic linkages. The oligonucleotide comprises a repeating backbone chiral-center pattern of [(Rp/Op)n(Sp)m]y including at least one RpSpSp pattern, natural phosphate linkages, and modified phosphorothioate linkages. The base sequence is at least 75% identical or complementary to a target sequence in a RHO gene or transcript and is complementary to the RHO sequence at SNP rs104893768.

The compositions provide allele-specific targeting directed to pathogenic variants such as P23H to selectively suppress mutant RHO transcripts or products while sparing wild-type RHO expression via RNase H-mediated knockdown or RNA interference. Controlled backbone stereochemistry, specific Rp linkage positions, and modified sugars tune oligonucleotide stability, delivery, efficacy, and toxicity profiles while improving knockdown activity and reducing off-target effects in screening results.

Claims Coverage

The relevant claim set identifies one independent claim comprising three inventive features directed to backbone stereochemistry, linkage composition, and sequence specificity.

Stereodefined chiral backbone pattern

The oligonucleotide comprises a plurality of chiral internucleotidic linkages with stereodefined linkage phosphorus arranged in the repeating pattern [(Rp/Op)n(Sp)m]y, where n is 1–10, m is 1–50, and y is 2–10, wherein at least one pattern comprises RpSpSp.

Natural phosphate and phosphorothioate linkages

The oligonucleotide comprises a natural phosphate linkage and one or more modified internucleotidic linkages, each independently being a phosphorothioate internucleotidic linkage.

Target sequence complementary at SNP rs104893768

The oligonucleotide base sequence is at least 75% identical or complementary to a target sequence in a RHO gene or transcript and is complementary to a RHO sequence at SNP rs104893768.

The independent claim covers an oligonucleotide combining a stereodefined chiral backbone pattern, natural phosphate and phosphorothioate linkages, and a target sequence complementary to RHO at SNP rs104893768.

Stated Advantages

Controlled backbone stereochemistry and structural features enable improved knockdown activity and allele selectivity while reducing off-target effects.

Selecting the Rp linkage position can improve RHO knockdown and allele selectivity, converting relatively inactive stereorandom or stereopure oligonucleotides into active designs.

The oligonucleotides achieve allele-specific knockdown of disease-associated RHO variants, including P23H, while preferentially sparing wild-type RHO.

G:U wobble substitutions are proposed to reduce off-target silencing.

Chirally controlled compositions and linkage choices tune delivery, stability, efficacy, and selectivity while providing improved toxicity profiles.

Oligonucleotides demonstrate strong mutant-selective knockdown in screening results.

Documented Applications

Allele-specific suppression of RHO expression, reducing mutant RHO transcripts or products, or decreasing RHO target activity.

Methods to prevent, treat, or ameliorate a RHO-related condition, disorder, or disease, specifically including retinopathy and retinitis pigmentosa, in a susceptible or affected subject.

Allele-specific treatment guided by phasing SNPs with pathogenic variants, as well as pan-specific RHO knockdown.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.